|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ITGB6 |
Gene summary for ITGB6 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ITGB6 | Gene ID | 3694 |
| Gene name | integrin subunit beta 6 | |
| Gene Alias | AI1H | |
| Cytomap | 2q24.2 | |
| Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | P18564 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 3694 | ITGB6 | CCI_2 | Human | Cervix | CC | 5.22e-10 | 1.20e+00 | 0.5249 |
| 3694 | ITGB6 | CCI_3 | Human | Cervix | CC | 3.15e-15 | 1.00e+00 | 0.516 |
| 3694 | ITGB6 | Tumor | Human | Cervix | CC | 7.28e-12 | 4.07e-01 | 0.1241 |
| 3694 | ITGB6 | sample1 | Human | Cervix | CC | 2.25e-03 | 3.02e-01 | 0.0959 |
| 3694 | ITGB6 | sample3 | Human | Cervix | CC | 3.03e-18 | 4.71e-01 | 0.1387 |
| 3694 | ITGB6 | T1 | Human | Cervix | CC | 1.15e-16 | 4.75e-01 | 0.0918 |
| 3694 | ITGB6 | T3 | Human | Cervix | CC | 1.06e-16 | 4.82e-01 | 0.1389 |
| 3694 | ITGB6 | P1T-E | Human | Esophagus | ESCC | 4.08e-02 | 2.53e-01 | 0.0875 |
| 3694 | ITGB6 | P2T-E | Human | Esophagus | ESCC | 1.10e-49 | 1.06e+00 | 0.1177 |
| 3694 | ITGB6 | P4T-E | Human | Esophagus | ESCC | 4.71e-02 | 1.84e-01 | 0.1323 |
| 3694 | ITGB6 | P5T-E | Human | Esophagus | ESCC | 2.39e-12 | 1.86e-01 | 0.1327 |
| 3694 | ITGB6 | P8T-E | Human | Esophagus | ESCC | 1.02e-09 | 1.61e-01 | 0.0889 |
| 3694 | ITGB6 | P11T-E | Human | Esophagus | ESCC | 7.60e-16 | 1.47e+00 | 0.1426 |
| 3694 | ITGB6 | P20T-E | Human | Esophagus | ESCC | 8.81e-24 | 1.04e+00 | 0.1124 |
| 3694 | ITGB6 | P21T-E | Human | Esophagus | ESCC | 1.15e-09 | 3.31e-01 | 0.1617 |
| 3694 | ITGB6 | P23T-E | Human | Esophagus | ESCC | 8.15e-14 | 5.67e-01 | 0.108 |
| 3694 | ITGB6 | P24T-E | Human | Esophagus | ESCC | 2.37e-31 | 1.25e+00 | 0.1287 |
| 3694 | ITGB6 | P26T-E | Human | Esophagus | ESCC | 2.09e-13 | 7.13e-02 | 0.1276 |
| 3694 | ITGB6 | P36T-E | Human | Esophagus | ESCC | 3.53e-22 | 1.46e+00 | 0.1187 |
| 3694 | ITGB6 | P37T-E | Human | Esophagus | ESCC | 1.18e-22 | 7.63e-01 | 0.1371 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000931424 | Skin | cSCC | response to radiation | 166/4864 | 456/18723 | 4.37e-07 | 8.41e-06 | 166 |
| GO:004206029 | Skin | cSCC | wound healing | 152/4864 | 422/18723 | 2.66e-06 | 4.26e-05 | 152 |
| GO:001021225 | Skin | cSCC | response to ionizing radiation | 64/4864 | 148/18723 | 3.64e-06 | 5.50e-05 | 64 |
| GO:003158926 | Skin | cSCC | cell-substrate adhesion | 130/4864 | 363/18723 | 1.87e-05 | 2.23e-04 | 130 |
| GO:000722924 | Skin | cSCC | integrin-mediated signaling pathway | 47/4864 | 107/18723 | 4.21e-05 | 4.43e-04 | 47 |
| GO:007155917 | Skin | cSCC | response to transforming growth factor beta | 95/4864 | 256/18723 | 5.21e-05 | 5.31e-04 | 95 |
| GO:007156025 | Skin | cSCC | cellular response to transforming growth factor beta stimulus | 92/4864 | 250/18723 | 9.65e-05 | 8.99e-04 | 92 |
| GO:000716024 | Skin | cSCC | cell-matrix adhesion | 85/4864 | 233/18723 | 2.43e-04 | 1.98e-03 | 85 |
| GO:004440929 | Skin | cSCC | entry into host | 59/4864 | 151/18723 | 2.75e-04 | 2.22e-03 | 59 |
| GO:004671829 | Skin | cSCC | viral entry into host cell | 56/4864 | 144/18723 | 4.46e-04 | 3.42e-03 | 56 |
| GO:000257324 | Skin | cSCC | myeloid leukocyte differentiation | 76/4864 | 208/18723 | 4.75e-04 | 3.60e-03 | 76 |
| GO:000717917 | Skin | cSCC | transforming growth factor beta receptor signaling pathway | 69/4864 | 198/18723 | 3.39e-03 | 1.84e-02 | 69 |
| GO:0036363 | Skin | cSCC | transforming growth factor beta activation | 7/4864 | 10/18723 | 4.43e-03 | 2.29e-02 | 7 |
| GO:003032417 | Skin | cSCC | lung development | 60/4864 | 177/18723 | 1.14e-02 | 4.97e-02 | 60 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0451010 | Cervix | CC | Focal adhesion | 59/1267 | 203/8465 | 1.53e-07 | 1.84e-06 | 1.09e-06 | 59 |
| hsa0481016 | Cervix | CC | Regulation of actin cytoskeleton | 64/1267 | 229/8465 | 2.24e-07 | 2.59e-06 | 1.53e-06 | 64 |
| hsa051657 | Cervix | CC | Human papillomavirus infection | 74/1267 | 331/8465 | 1.70e-04 | 1.02e-03 | 6.03e-04 | 74 |
| hsa0451014 | Cervix | CC | Focal adhesion | 59/1267 | 203/8465 | 1.53e-07 | 1.84e-06 | 1.09e-06 | 59 |
| hsa0481017 | Cervix | CC | Regulation of actin cytoskeleton | 64/1267 | 229/8465 | 2.24e-07 | 2.59e-06 | 1.53e-06 | 64 |
| hsa0516512 | Cervix | CC | Human papillomavirus infection | 74/1267 | 331/8465 | 1.70e-04 | 1.02e-03 | 6.03e-04 | 74 |
| hsa0516510 | Esophagus | ESCC | Human papillomavirus infection | 215/4205 | 331/8465 | 7.86e-09 | 7.12e-08 | 3.65e-08 | 215 |
| hsa0451020 | Esophagus | ESCC | Focal adhesion | 127/4205 | 203/8465 | 1.25e-04 | 4.99e-04 | 2.56e-04 | 127 |
| hsa0481028 | Esophagus | ESCC | Regulation of actin cytoskeleton | 133/4205 | 229/8465 | 5.94e-03 | 1.48e-02 | 7.56e-03 | 133 |
| hsa041517 | Esophagus | ESCC | PI3K-Akt signaling pathway | 197/4205 | 354/8465 | 1.24e-02 | 2.83e-02 | 1.45e-02 | 197 |
| hsa0516515 | Esophagus | ESCC | Human papillomavirus infection | 215/4205 | 331/8465 | 7.86e-09 | 7.12e-08 | 3.65e-08 | 215 |
| hsa04510111 | Esophagus | ESCC | Focal adhesion | 127/4205 | 203/8465 | 1.25e-04 | 4.99e-04 | 2.56e-04 | 127 |
| hsa04810112 | Esophagus | ESCC | Regulation of actin cytoskeleton | 133/4205 | 229/8465 | 5.94e-03 | 1.48e-02 | 7.56e-03 | 133 |
| hsa0415114 | Esophagus | ESCC | PI3K-Akt signaling pathway | 197/4205 | 354/8465 | 1.24e-02 | 2.83e-02 | 1.45e-02 | 197 |
| hsa045108 | Lung | IAC | Focal adhesion | 59/1053 | 203/8465 | 1.31e-10 | 1.06e-08 | 7.06e-09 | 59 |
| hsa051656 | Lung | IAC | Human papillomavirus infection | 71/1053 | 331/8465 | 1.88e-06 | 7.63e-05 | 5.06e-05 | 71 |
| hsa0481012 | Lung | IAC | Regulation of actin cytoskeleton | 49/1053 | 229/8465 | 7.94e-05 | 1.17e-03 | 7.79e-04 | 49 |
| hsa054126 | Lung | IAC | Arrhythmogenic right ventricular cardiomyopathy | 22/1053 | 77/8465 | 1.15e-04 | 1.49e-03 | 9.88e-04 | 22 |
| hsa04512 | Lung | IAC | ECM-receptor interaction | 20/1053 | 89/8465 | 5.65e-03 | 2.45e-02 | 1.63e-02 | 20 |
| hsa05410 | Lung | IAC | Hypertrophic cardiomyopathy | 20/1053 | 90/8465 | 6.44e-03 | 2.68e-02 | 1.78e-02 | 20 |
| Page: 1 2 3 4 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| FN1 | ITGAV_ITGB6 | FN1_ITGAV_ITGB6 | FN1 | Breast | Healthy |
| TNC | ITGAV_ITGB6 | TNC_ITGAV_ITGB6 | TENASCIN | Breast | Healthy |
| TNXB | ITGAV_ITGB6 | TNXB_ITGAV_ITGB6 | TENASCIN | Breast | Healthy |
| FN1 | ITGAV_ITGB6 | FN1_ITGAV_ITGB6 | FN1 | Cervix | CC |
| SPP1 | ITGAV_ITGB6 | SPP1_ITGAV_ITGB6 | SPP1 | Cervix | CC |
| TNC | ITGAV_ITGB6 | TNC_ITGAV_ITGB6 | TENASCIN | Cervix | CC |
| TNXB | ITGAV_ITGB6 | TNXB_ITGAV_ITGB6 | TENASCIN | Cervix | CC |
| FN1 | ITGAV_ITGB6 | FN1_ITGAV_ITGB6 | FN1 | CRC | ADJ |
| TNXB | ITGAV_ITGB6 | TNXB_ITGAV_ITGB6 | TENASCIN | CRC | ADJ |
| TNXB | ITGAV_ITGB6 | TNXB_ITGAV_ITGB6 | TENASCIN | CRC | FAP |
| TNC | ITGAV_ITGB6 | TNC_ITGAV_ITGB6 | TENASCIN | Esophagus | ESCC |
| TNXB | ITGAV_ITGB6 | TNXB_ITGAV_ITGB6 | TENASCIN | Esophagus | ESCC |
| FN1 | ITGAV_ITGB6 | FN1_ITGAV_ITGB6 | FN1 | HNSCC | OSCC |
| TNC | ITGAV_ITGB6 | TNC_ITGAV_ITGB6 | TENASCIN | HNSCC | OSCC |
| TNXB | ITGAV_ITGB6 | TNXB_ITGAV_ITGB6 | TENASCIN | HNSCC | OSCC |
| FN1 | ITGAV_ITGB6 | FN1_ITGAV_ITGB6 | FN1 | HNSCC | Precancer |
| TNC | ITGAV_ITGB6 | TNC_ITGAV_ITGB6 | TENASCIN | HNSCC | Precancer |
| TNXB | ITGAV_ITGB6 | TNXB_ITGAV_ITGB6 | TENASCIN | HNSCC | Precancer |
| FN1 | ITGAV_ITGB6 | FN1_ITGAV_ITGB6 | FN1 | Lung | IAC |
| TNC | ITGAV_ITGB6 | TNC_ITGAV_ITGB6 | TENASCIN | Lung | IAC |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ITGB6 | SNV | Missense_Mutation | novel | c.1727N>T | p.Cys576Phe | p.C576F | P18564 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A2-A4S1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ITGB6 | SNV | Missense_Mutation | rs756187131 | c.1754N>T | p.Ser585Phe | p.S585F | P18564 | protein_coding | deleterious(0) | probably_damaging(0.91) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| ITGB6 | SNV | Missense_Mutation | c.1212N>C | p.Lys404Asn | p.K404N | P18564 | protein_coding | deleterious(0) | possibly_damaging(0.903) | TCGA-BH-A0DZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD | |
| ITGB6 | SNV | Missense_Mutation | rs552791527 | c.1916G>A | p.Gly639Asp | p.G639D | P18564 | protein_coding | tolerated(0.22) | benign(0.001) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ITGB6 | SNV | Missense_Mutation | rs760815776 | c.2344N>A | p.Val782Ile | p.V782I | P18564 | protein_coding | tolerated_low_confidence(0.44) | benign(0) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ITGB6 | SNV | Missense_Mutation | novel | c.716C>A | p.Pro239His | p.P239H | P18564 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-E2-A1LE-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | herceptin | PD |
| ITGB6 | SNV | Missense_Mutation | rs376329044 | c.1910N>T | p.Ala637Val | p.A637V | P18564 | protein_coding | tolerated(0.22) | benign(0.174) | TCGA-E9-A1NG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | letrozole | SD |
| ITGB6 | insertion | Nonsense_Mutation | novel | c.889_890insATATCAGTGAGGATAGCCGCATGTTGTCTTTTAGTCAGTGAGGG | p.Ser297AsnfsTer14 | p.S297Nfs*14 | P18564 | protein_coding | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD | ||
| ITGB6 | insertion | Nonsense_Mutation | novel | c.471_472insACACATTATGCAGGTGATGGTGGAGGACAGATTGCTTTGTGA | p.Ser157_Arg158insThrHisTyrAlaGlyAspGlyGlyGlyGlnIleAlaLeuTer | p.S157_R158insTHYAGDGGGQIAL* | P18564 | protein_coding | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| ITGB6 | SNV | Missense_Mutation | rs751132914 | c.821N>G | p.Ser274Cys | p.S274C | P18564 | protein_coding | deleterious(0.04) | probably_damaging(0.999) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 3694 | ITGB6 | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE | inhibitor | 385612210 | ||
| 3694 | ITGB6 | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE | inhibitor | CHEMBL2109623 | STX-100 | |
| 3694 | ITGB6 | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE | antagonist | CHEMBL1743032 | INTETUMUMAB | |
| 3694 | ITGB6 | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE | GLPG0187 | GLPG-0187 | ||
| 3694 | ITGB6 | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE | inhibitor | CHEMBL2109621 | ABITUZUMAB |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |